Our Quarterly Activities Report for the period ending 30 September 2025 has been released. View the full report here: 🔽 https://t.co/S7j6MnL6nv $NTI #Neurotech #Biotech #RettSyndrome #Autism #PANDAS #PANS

In the latest episode of @StockheadAU's Who’s Who on the ASX, host Tylah Tully highlights #NTI164, our broad-spectrum oral cannabinoid therapy in development for paediatric neurological disorders. Read the full $NTI article here:

2025 Annual Report View the full Annual Report here: https://t.co/HOt1ZEGldF $NTI #Neurotech #Biotech #RettSyndrome #Autism #PANDAS #PANS

📰Neurotech Secures Rare Pediatric Disease Designation for NTI164 in Rett Syndrome | $NTI Media coverage by @techinvestmag. https://t.co/9xVjNbODpg #NTI #Neurotech #Biotech #RettSyndrome

October 9 is PANS/PANDAS Awareness Day, a time to recognise the sudden and challenging nature of these neuroimmune disorders. At Neurotech, we’re advancing NTI164 with a focus on immune regulation and gene expression; two biological pathways central to what drives PANDAS/PANS.

Neurotech scores US FDA rare disease win for NTI164 in Rett syndrome | $NTI Media coverage by @australian https://t.co/zH5yhJ3tob #Neurotech #RettSyndrome #Biotech #ASX #ASXNews

We’ve received Rare Pediatric Disease Designation from the US FDA for NTI164 in Rett syndrome. This milestone recognition complements the existing Orphan Drug Designation and strengthens our position in developing therapies for rare and underserved neurological disorders. The

CEO Anthony Filippis outlines how Neurotech is advancing NTI164 through clinical development in the latest article featured in Stockhead. Anthony discusses the initiation of the Authorised Prescriber program and highlights our focus on accelerating regulatory pathways, creating

October marks Rett Syndrome Awareness Month, a time to recognise the challenges faced by children and families living with this rare neurological disorder. Rett Syndrome affects approximately 1 in 10,000-15,000 girls, and currently, there is no cure. It is caused by mutations in

$NTI coverage in the @australian via @StockheadAU – "Neurotech launches Authorised Prescriber program for its neurodevelopmental disorders therapy". Click here to read: https://t.co/gyQrvtEHZd

We are pleased to announce the commencement of an Authorised Prescriber (AP) program for our therapy NTI164, across a range of neurodevelopmental conditions for paediatric patients in Australia: https://t.co/6gPy6NyRRP The program will be managed by leading paediatric

Our Principal Investigator, Professor Russell Dale, who leads our Phase I/II PANDAS/PANS clinical trial, has had a new paper published in @Nature (Molecular Psychiatry). This recognition underscores the calibre of clinical leadership guiding NTI164’s development and builds

“We now have the clinical data, regulatory momentum, and leadership to deliver NTI164 to patients globally,” Chairman Mark Davies said. FY25 was a turning point,” Davies said. “With a strong clinical package, regulatory recognition, and an experienced team, Neurotech is

"In my clinical practice, I’ve seen how full-spectrum cannabinoid therapies can profoundly improve the lives of children with autism, Rett syndrome, and PANS." – Dr. Bonni Goldstein MD, Neurotech Chief Medical Advisor (USA). Dr. Goldstein supports NTI164, Neurotech’s consistent,

The U.S. is considering moving #marijuana from a Schedule I to a Schedule III substance, a change that could make life a lot easier for companies working with #cannabinoid-based medicines. While #NTI164 is already developed and trialled within Australia’s regulatory framework,

Our Managing Director & CEO, Anthony Filippis joined today’s “Deal Making: The Real Story” panel at the 2025 Bioshares Biotech Summit, alongside fellow biotech leaders sharing real-world lessons on navigating transactions, partnerships, and growth. Thanks to Bioshares for

We’ve been featured in @TheAustralian in an article exploring new treatments for Rett syndrome, a rare and complex paediatric neurological condition. Read more: https://t.co/srXl4wWrJD $NTI #Neurotech #ASX #NTI #RettSyndrome #NTI164 #PaediatricNeurology #CannabinoidTherapy

"Neurotech’s June quarter was marked by important clinical progress, growing international recognition, and further regulatory engagement for its lead investigational therapy #NTI164, a proprietary #CBDA-rich #cannabinoid formulation being developed for #paediatric neurological